Skip to main navigation
Barinthus Biotherapeutics logo
Top Navigation
  • Home
  • About Us
    • Overview
    • Our Team
    • A Name with Purpose
  • Technology
    • Overview
    • Viral Vector Platforms
    • Synthetic Platforms
  • Pipeline
    • Overview
    • Infectious Diseases
    • Autoimmunity
    • Cancer
  • Partnerships
    • Overview
    • Infectious Diseases
    • Autoimmunity
    • Cancer
  • Investors
    • Overview
    • News & Filings
    • Events & Presentations
    • Stock Information
    • Corporate Governance
    • Investor FAQs
    • Contact IR
  • Careers
    • Overview
    • Recruitment Companies
  • Contact
    • Overview
    • Patient Enquiries
Select Page

Annual Reports and AGM

Toolkit
  • Subscribe
  • RSS Feeds
  • Contact IR
  • Presentations
Sub Nav News & Filings
Press Releases
SEC Filings
Annual Reports and AGM
Quarterly Results
Annual Reports and AGM
Show all

Annual Reports

2022/2023

  • Form 10-K
  • Proxy statement 4.3 MB
  • Annual Report and Accounts for the Year Ended 31 December 2022 3.8 MB
  • Notice of Vaccitech plc Annual General Meeting 2023 653.6 KB
  • Form of UK Proxy Card 2023 606.3 KB
  • Poll Voting Results of the 2023 AGM 193.9 KB

Annual Reports

2021/2022

  • Form 10-K
  • Proxy statement 2.5 MB
  • Annual Report and Accounts for the Year Ended 31 December 2021 4.1 MB
  • Notice of Vaccitech plc Annual General Meeting 2022 410.4 KB
  • Form of UK Proxy Card 2022 510.2 KB

Barinthus Biotherapeutics plc

Unit 6-10
Zeus Building
Rutherford Avenue
Harwell OX11 0DF
United Kingdom

T: +44 (0)1865 818808

Footer Links
Home
About
Sitemap
Privacy Policy
Privacy Notice
Careers
Contact
Barinthus Biotherapeutics logo
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer.
© Barinthus Biotherapeutics 2023 All rights reserved.
Social Media Links
  • Follow us on X
  • Follow us on LinkedIn